NCT03882255View on ClinicalTrials.gov

A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 20, 2019

Primary Completion Date

August 26, 2019

Study Completion Date

August 26, 2019

Conditions
Healthy
Interventions
DRUG

Ponesimod dose range (2 - 20 mg)

Participants will receive ponesimod oral tablet at a dose of 2 mg in Treatment period 1 and as an up-titrating regimen (dose range: 2mg-20mg) in Treatments period 2.

DRUG

Placebo Propranolol

Participants will be administered placebo propranolol oral capsule from Day 1 to Day 19 in Treatment A of Treatment period 2.

DRUG

Propranolol 80 mg

Participants will receive propranolol 80 mg long acting oral capsule from Day 1 to Day 19 in Treatment B of Treatment period 2.

Trial Locations (1)

2060

SGS Clinical Pharmacology Unit (located in ZNA Stuivenberg), Antwerp

All Listed Sponsors
lead

Janssen Pharmaceutica N.V., Belgium

INDUSTRY

NCT03882255 - A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State | Biotech Hunter | Biotech Hunter